Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EUSA Finds Japanese Partner For Lead Product In Generics-turned-innovator Ohara

This article was originally published in PharmAsia News

Executive Summary

TOKYO - In-licensing firm EUSA Pharma established its first partnership in Japan, behind similar deals in South Korea and China, for its acute lymphoblastic leukemia treatment Erwinase (erwinia L-asparaginase)

You may also be interested in...

EUSA Wins U.S. Approval of Erwinaze; Shipping To Start Week Of Nov. 20

Eusa hopes the approval will help cement its efforts in the U.S., where it has been trying to build a strong presence for several years.

Novamed In-Licenses Products from Iroko and EUSA To Strengthen Cardiovascular And Oncology Pipeline

SHANGHAI - NovaMed Pharmaceuticals announced July 10 it has reached agreements with U.S.-based Iroko and U.K. firm EUSA Pharma to in-license Iroko's cardiovascular drugAggrastat (tirofiban) and EUSA's oncology drug Erwinase (crisantaspase)

EUSA Pharma Gains Foothold In U.S. Market With Cytogen Acquisition

Buyout positions U.K. drug maker to take on new licensing deals on both sides of the Atlantic; oncology filing planned within 12 months, EUSA tells the DAILY.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts